South Africa delivered the week’s clearest macroeconomic signal. According to Statistics South Africa, annual consumer inflation rose from 4.5% in May to 5.0% in June, its highest rate since June 2024. The composition was unusually stark, with transport costs rising sharply while food inflation eased. Elsewhere, household purchasing power and the regulation of medicine markets offered separate tests of how aggregate economic developments reach consumers.
A fuel-heavy inflation rebound
The inflation breakdown is as important as the headline figure. Statistics South Africa reported that transport prices rose by 12.7% over the year, largely reflecting a 34.3% increase in fuel prices, while food inflation declined to 1.6%. The contrast points to an uneven inflation picture rather than a uniform rise across major household spending categories.
This distinction matters for monetary policy. A relative price shock can reduce real household incomes without necessarily developing into persistent inflation. Underlying inflation measures and subsequent price-setting behaviour therefore deserve more attention than the headline rate alone.
Europe’s households remain in place
Europe’s household accounts offered a different kind of signal. Eurostat reported that real income per person was unchanged in the euro area during the first quarter and increased by 0.1% across the European Union. Real consumption per person was also unchanged in the euro area but declined by 0.2% in the EU, while the EU household saving rate increased by 0.2 percentage points.
The distinction is important. Stability in aggregate indicators can conceal weak momentum in living standards, while a small increase in income does not automatically translate into stronger household spending.
Medicine markets meet tougher enforcement
In the United States, the Federal Trade Commission settled its antitrust case against Caremark, requiring changes intended to improve transparency and the treatment of community pharmacies. The agency estimates that the agreement could save consumers as much as $8.5 billion over the next decade, partly through reforms addressing insulin-pricing practices.
Because the projected savings come from the regulator, the eventual test will be whether the reforms are implemented effectively and produce measurable consumer benefits.
In Britain, the Court of Appeal dismissed challenges to findings that Auden Mckenzie and Actavis UK had charged excessive prices for hydrocortisone tablets. According to the UK Competition and Markets Authority, the companies face penalties totalling £266 million. The price of the medicine reportedly increased from less than £1 to more than £70 per pack, while annual NHS expenditure rose from approximately £500,000 to more than £80 million.
Together, the US and UK cases illustrate how competition policy can function as a tool of cost control in concentrated pharmaceutical supply chains. However, legal victories and regulatory settlements must still translate into durable gains for consumers, pharmacies, and public healthcare systems.